Literature DB >> 26556305

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.

Melissa A Gray1, Ran N Tao2, Sandra M DePorter1, David A Spiegel2, Brian R McNaughton3,4.   

Abstract

We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  HER2; activation immunotherapeutic; breast cancer; immunotherapy; nanobody

Mesh：

Substances：

Year:  2015        PMID： 26556305      PMCID： PMC5199233          DOI： 10.1002/cbic.201500591

Source DB:  PubMed          Journal:  Chembiochem        ISSN： 1439-4227            Impact factor:   3.164


  22 in total

1.  The use of mRNA display to select high-affinity protein-binding peptides.

Authors:  D S Wilson; A D Keefe; J W Szostak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Structural and thermodynamic analysis of the GFP:GFP-nanobody complex.

Authors:  Marta H Kubala; Oleksiy Kovtun; Kirill Alexandrov; Brett M Collins
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

3.  General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.

Authors:  Cécile Vincke; Remy Loris; Dirk Saerens; Sergio Martinez-Rodriguez; Serge Muyldermans; Katja Conrath
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

Review 4.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

5.  The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker.

Authors:  T Cooke; J Reeves; A Lannigan; P Stanton
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

Review 6.  Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

Authors:  Kate McKeage; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Concentrations of three hapten-binding immunoglobulins in pooled normal human serum.

Authors:  K Karjalainen; O Mäkelä
Journal:  Eur J Immunol       Date:  1976-02       Impact factor: 5.532

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-11-15       Impact factor: 2.408

Review 10.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.

Authors:  J Carlsson; H Nordgren; J Sjöström; K Wester; K Villman; N O Bengtsson; B Ostenstad; H Lundqvist; C Blomqvist
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640
View more
  14 in total

1.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

2.  Evaluation of Nanobody Conjugates and Protein Fusions as Bioanalytical Reagents.

Authors:  Virginia J Bruce; Brian R McNaughton
Journal:  Anal Chem       Date:  2017-03-20       Impact factor: 6.986

3.  pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity.

Authors:  Janessa Wehr; Eden L Sikorski; Elizabeth Bloch; Mary S Feigman; Noel J Ferraro; Trevor R Baybutt; Adam E Snook; Marcos M Pires; Damien Thévenin
Journal:  J Med Chem       Date:  2020-03-30       Impact factor: 7.446

Review 4.  Recent progress in enzymatic protein labelling techniques and their applications.

Authors:  Yi Zhang; Keun-Young Park; Kiall F Suazo; Mark D Distefano
Journal:  Chem Soc Rev       Date:  2018-09-27       Impact factor: 54.564

5.  Nanobody Conjugates for Targeted Cancer Therapy and Imaging.

Authors:  Wei Kang; Chuanfeng Ding; Danni Zheng; Xiao Ma; Lun Yi; Xinyi Tong; Chuang Wu; Chuang Xue; Yongsheng Yu; Qian Zhou
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

6.  Selection and characterization of specific nanobody against bovine virus diarrhea virus (BVDV) E2 protein.

Authors:  Tiansen Li; Meiling Huang; Hongran Xiao; Guoqi Zhang; Jinhua Ding; Peng Wu; Hui Zhang; Jinliang Sheng; Chuangfu Chen
Journal:  PLoS One       Date:  2017-06-05       Impact factor: 3.240

Review 7.  Mechanism of immune evasion in breast cancer.

Authors:  Mozhi Wang; Changwang Zhang; Yongxi Song; Zhenning Wang; Yaojia Wang; Fang Luo; Yujie Xu; Yi Zhao; Zhonghua Wu; Yingying Xu
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147

Review 8.  Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.

Authors:  Dominik Schumacher; Jonas Helma; Anselm F L Schneider; Heinrich Leonhardt; Christian P R Hackenberger
Journal:  Angew Chem Int Ed Engl       Date:  2018-01-26       Impact factor: 15.336

9.  Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies.

Authors:  Haofei Hong; Zhifang Zhou; Kun Zhou; Shaozhong Liu; Zhongwu Guo; Zhimeng Wu
Journal:  Chem Sci       Date:  2019-08-28       Impact factor: 9.825

Review 10.  Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.

Authors:  E Krasniqi; G Barchiesi; L Pizzuti; M Mazzotta; A Venuti; M Maugeri-Saccà; G Sanguineti; G Massimiani; D Sergi; S Carpano; P Marchetti; S Tomao; T Gamucci; R De Maria; F Tomao; C Natoli; N Tinari; G Ciliberto; M Barba; P Vici
Journal:  J Hematol Oncol       Date:  2019-10-29       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.